Product Biomarkers
Apply PSI™ to CAR T-cell product release in a way that correlates to in vivo activity1
Detect the potent functional immune cell subsets that drive response and accelerate translational research.
How our Award-Winning IsoLight Single-Cell System is Making a Difference
Solution
IsoPlexis’ PSI is able to stratify responders and non-responders
Finding
Polyfunctional strength was found to correlate with objective response to CAR-T cell therapy, where other pre-infusion metrics did not
Follow Our Data
See the latest published data in Cell Therapy
PSI of the pre-infusion CAR-T cell products showed significant correlation with the objective response of patients. The PSI, measured across a cohort of 20 patients, combined the CD4+ and CD8+ CAR-T response to CD19-K562 stimulation.
The average PSI of the responder subgroup was more than twice as high as the PSI of the non-responders, a difference that was shown to be statistically significant (p = 0.0119).1
Solution
Detect Critical Differences
PSI outperformed other pre-infusion metrics, including IFN-g co-culture cytokine intensity, ratio of CD4+ to CD8+ T cells, and various T cell phenotype frequencies.1
PSI was the only metric that statistically differentiated responding from non-responding patients. The correlation of PSI with clinical outcome indicates the metric’s potential as a biomarker for guiding personalized CAR-T cell treatments and predicting therapeutic efficacy.1
[1] Reference: Rossi & Paczkowski et al, Blood 2018